Paper39802172
Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword.
Amesz JH and 5 others. J Mol Cell Cardiol Plus, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword. Papers, record 39802172. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39802172
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30631059 | Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro. | Nat Commun | 2019 | https://conductscience.org/library/papers/30631059 | PubMed |
| 2 | 27012405 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. | J Am Coll Cardiol | 2016 | https://conductscience.org/library/papers/27012405 | PubMed |
| 3 | 3608112 | Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. | Circ Res | 1987 | https://conductscience.org/library/papers/3608112 | PubMed |
| 4 | 5640345 | Systolic time intervals in heart failure in man. | Circulation | 1968 | https://conductscience.org/library/papers/5640345 | PubMed |
| 5 | 18056765 | Sarcomeric proteins and inherited cardiomyopathies. | Cardiovasc Res | 2008 | https://conductscience.org/library/papers/18056765 | PubMed |
| 6 | 4227924 | ATPase activity of myosin correlated with speed of muscle shortening. | J Gen Physiol | 1967 | https://conductscience.org/library/papers/4227924 | PubMed |
| 7 | 20498236 | Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. | Circ Heart Fail | 2010 | https://conductscience.org/library/papers/20498236 | PubMed |
| 8 | 35852527 | Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. | JAMA | 2022 | https://conductscience.org/library/papers/35852527 | PubMed |
| 9 | 26140433 | The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat. | Br J Pharmacol | 2015 | https://conductscience.org/library/papers/26140433 | PubMed |
| 10 | 31863532 | Association between systolic ejection time and outcomes in heart failure by ejection fraction. | Eur J Heart Fail | 2020 | https://conductscience.org/library/papers/31863532 | PubMed |
| 11 | 27914656 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/27914656 | PubMed |
| 12 | 32231589 | The Degree of t-System Remodeling Predicts Negative Force-Frequency Relationship and Prolonged Relaxation Time in Failing Human Myocardium. | Front Physiol | 2020 | https://conductscience.org/library/papers/32231589 | PubMed |
| 13 | 16418450 | Mechanisms and use of calcium-sensitizing agents in the failing heart. | Circulation | 2006 | https://conductscience.org/library/papers/16418450 | PubMed |
| 14 | 35030072 | Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations. | Am J Physiol Heart Circ Physiol | 2022 | https://conductscience.org/library/papers/35030072 | PubMed |
| 15 | 34096321 | Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium. | J Am Heart Assoc | 2021 | https://conductscience.org/library/papers/34096321 | PubMed |
| 16 | 27322915 | The myosin activator omecamtiv mecarbil: a promising new inotropic agent. | Can J Physiol Pharmacol | 2016 | https://conductscience.org/library/papers/27322915 | PubMed |
| 17 | 27206819 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. | Eur Heart J | 2016 | https://conductscience.org/library/papers/27206819 | PubMed |
| 18 | 17360992 | The failing heart--an engine out of fuel. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17360992 | PubMed |
| 19 | 21616079 | Cardiac myosin activation part 1: from concept to clinic. | J Mol Cell Cardiol | 2011 | https://conductscience.org/library/papers/21616079 | PubMed |
| 20 | 29030372 | Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium. | Circ Heart Fail | 2017 | https://conductscience.org/library/papers/29030372 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42126521 | Advances in Living Myocardial Slice Technology for Heart Failure Research. | Curr Heart Fail Rep | 2026 | https://conductscience.org/library/papers/42126521 | PubMed |
| 40831223 | Insights from electromechanical simulations to assess omecamtiv mecarbil efficacy in heart failure. | J Physiol | 2026 | https://conductscience.org/library/papers/40831223 | PubMed |
| 40354127 | Living myocardial slices: walking the path towards standardization. | Cardiovasc Res | 2025 | https://conductscience.org/library/papers/40354127 | PubMed |
| 40001693 | Acute Biomechanical Effects of Cardiac Contractility Modulation in Living Myocardial Slices from End-Stage Heart Failure Patients. | Bioengineering (Basel) | 2025 | https://conductscience.org/library/papers/40001693 | PubMed |
| 39802436 | Charting our course: Indexing milestones for JMCC PLUS. | J Mol Cell Cardiol Plus | 2024 | https://conductscience.org/library/papers/39802436 | PubMed |
| 39802175 | Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure. | J Mol Cell Cardiol Plus | 2023 | https://conductscience.org/library/papers/39802175 | PubMed |
| 38790961 | Emerging Concepts of Mechanisms Controlling Cardiac Tension: Focus on Familial Dilated Cardiomyopathy (DCM) and Sarcomere-Directed Therapies. | Biomedicines | 2024 | https://conductscience.org/library/papers/38790961 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MYH14 | 79784 | PubTator's text mining | https://conductscience.org/library/genes/79784 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39802172
GET https://conductscience.org/api/papers/v1/39802172/references?page=2